# Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

> **NCT04533022** · PHASE2 · COMPLETED · sponsor: **Vicore Pharma AB** · enrollment: 52 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** C21

## Key facts

- **NCT ID:** NCT04533022
- **Lead sponsor:** Vicore Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-13
- **Primary completion:** 2024-03-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04533022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04533022, "Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04533022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*